As a world-leading digital healthcare company we produce innovative medical technologies which enable faster and more accurate diagnosis of neurological diseases such as dementia.
Alzheimer's Disease and other types of dementia (such as vascular dementia, dementia with lewy bodies due to Parkinson’s disease, and frontal temporal dementia) are recognised as being devastating, not only for the patient but also for their families and carers. With rapidly aging populations in the developed economies, the health and social care costs of dementia are expected to become increasingly hard to sustain for healthcare systems. An estimated 800,000 people in the UK currently suffer from dementia and over the next 30 years, the number of sufferers in the country is forecast to reach approximately 1,700,000.
Why Diagnose Early?
The combination of earlier diagnosis of dementia and consequently earlier clinical intervention is increasingly believed to contribute to improving the lives of people with dementia, their families and carers and to controlling health and social care costs. Recent studies have indicated that currently available pharmaceutical interventions (such as acetylcholinesterase inhibitors) as well as psychological and psychosocial caregiver interventions (such as counselling and support) can, if applied earlier in the disease course, produce improved cognitive outcomes for patients. Such improvement can reduce the strain for carers during the early stages of the disease allowing them to provide care at home for longer. This delays the time to institutionalisation and therefore extends the period of relatively independent living.
When the diagnosis for Alzheimer’s disease or other serious brain diseases is positive patients can quickly access the treatment and support they need to extend their independent life.
When the diagnosis is negative, Assessa can be used in the clinic to reassure patients that dementia is not the cause of their symptoms.
What is IXICO doing to help?
Decision-support tools to aid diagnosis
At IXICO we are developing technologies that will help healthcare professionals looking to diagnose dementia and detect the underlying causes. Our Assessa tool is a medical device that enhances human judgement by providing a digital means of measuring, comparing and combining information about the brain. Using MRI images our tool has been shown by independent researchers to be more effective than other currently available approaches including radiological scoring or manual delineation of brain structures for predicting patients progressing to Alzheimer’s disease.
Users upload the MRI images to our web based tool and a report is returned to the clinician with quantitiative indications of the degree of atrophy in the medial temporal lobe of the brain. This region is most affected by the disease process, inparticular the hippocampus. By comparing the volume of the hoppocampus and other regions to age matched, healthy subjects we can provide an indication to the clinician as to the likely severity of the disease.
Want to know more?
Please note medical device certification currently applies only to the EU.